Drug Trial Radar · NCT05063253
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
208
Planned (sponsor's estimate)
Start
Oct 2021
Primary completion
Mar 2024
Study completion Mar 2024
Sponsor
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.
Conditions
- Type 2 Diabetes Mellitus
Interventions
TG103Drug
TG103 injection, SC, once weekly
PlaceboDrug
Placebo, SC, once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20Time frame: Baseline through Day 141 (the end of the 20-week treatment)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.